Tag: Airsupra

In January 2023, the FDA approved Airsupra (albuterol/budesonide), the first and only dual-action rescue inhaler to combine a short-acting beta-agonist (SABA) with an inhaled corticosteroid (ICS). This development marks a significant shift in respiratory care, offering a new approach to managing asthma attacks and underlying inflammation simultaneously.

According to clinical trial data published in the *New England Journal of Medicine*, the combination inhaler AIRSUPRA demonstrated a significantly lower risk of severe asthma exacerbations compared to albuterol alone. So, is AIRSUPRA better than albuterol? The answer depends on a patient's specific treatment needs, as AIRSUPRA combines a bronchodilator with an anti-inflammatory corticosteroid, offering a different therapeutic approach to asthma management than albuterol alone.

Asthma affects approximately 25 million Americans, with many still experiencing breakthrough symptoms despite daily maintenance therapy. The newest inhaler for asthma to significantly change rescue treatment is AIRSUPRA, a dual-action option approved for adults that addresses both symptoms and inflammation.